Last updated: February 27, 2026
What is NDC 49884-0252?
NDC 49884-0252 corresponds to Vasopressin (Vasostrict). It is a synthetic form of the naturally occurring hormone vasopressin, used primarily for vasodilatory shock, cardiac arrest, diabetes insipidus, and other conditions requiring vasopressor support.
Market Overview
Current Market Size
- The U.S. demand for vasopressin products has remained relatively stable over the past five years.
- Estimated annual sales volume: approximately 1.2 million units (vials).
- Market value: roughly $150 million annually (IQVIA, 2022 data).
Key Competitors
| Product Name |
Manufacturer |
Formulation |
Price per Unit |
Market Share |
| Vasostrict (Vasopressin) |
Fresenius Kabi |
20 units/vial |
$12.50 |
60% |
| Vasopressin Injection (Generics) |
Multiple |
20 units/vial |
$9.80 - $11.20 |
30% |
| Other formulations |
Various |
20 units/vial |
$13.00+ |
10% |
Regulatory Status
- FDA approval: Vasostrict has FDA approval for multiple indications.
- Pricing regulation: No recent price controls; pricing influenced by supply chain dynamics.
Price Projections
Historical Price Trends
- 2018: Average unit price ~$9.50
- 2020: Increased to ~$11.20 amid supply constraints
- 2022: Stabilized at ~$12.50 for brand-name product
Factors Affecting Future Price
- Manufacturing costs: Potential increases due to raw material prices.
- Market competition: Entry of generics could drive prices down.
- Supply chain dynamics: COVID-19 pandemic disruptions caused price volatility.
- Regulatory environment: Any price regulation or reimbursement changes could affect retail prices.
Forecasted Price Range (Next 2-3 Years)
| Year |
Estimated Price per Vial |
Comments |
| 2023 |
$13.00 - $14.00 |
Slight increase driven by raw material costs |
| 2024 |
$13.50 - $15.00 |
Market saturation might moderate growth |
| 2025 |
$14.00 - $16.00 |
Potential influence of new generic entrants |
Market Dynamics & Opportunities
- Demand remains steady due to critical indications.
- Limited generic competition allows stable pricing.
- Potential for biosimilar development if patent protections expire.
- Manufacturer focus on expanding indications could influence demand and pricing.
Risks
- Patent expirations could lead to increased generic competition, lowering prices.
- Regulatory changes or reimbursement policies might restrict price increases.
- Supply chain disruptions can cause price volatility.
Key Takeaways
- The market for vasopressin (NDC 49884-0252) is stable, valued at around $150 million annually.
- Price per vial has increased from approximately $9.50 in 2018 to $12.50 in 2022.
- Future prices are projected to grow modestly, reaching up to $16 per vial by 2025.
- Generics and biosimilars can influence price trends if market entry occurs.
- Market stability depends on continued demand for vasopressor therapy and supply chain robustness.
FAQs
1. Is there significant generic competition for vasopressin?
Yes, several generics are available, which could intensify competition and pressure prices downward once patents expire.
2. How do regulatory policies affect vasopressin pricing?
Pricing is not directly regulated but could be influenced by reimbursement policies and drug formularies.
3. What are the primary driving factors behind price increases?
Raw material costs, supply chain constraints, and limited competition currently drive prices upward.
4. Could biosimilars impact the market?
Potentially; if biosimilars are developed and approved, they could lower prices by increasing competition.
5. What is the outlook for demand?
Demand remains steady due to vasopressin’s critical indications and lack of alternative therapies.
Sources
[1] IQVIA. (2022). U.S. pharmaceutical sales data.
[2] FDA. (2022). Vasopressin approval details.
